The global market for pooled CRISPR screening is poised for significant growth, bolstered by advancements in gene-editing technologies and increasing research in functional genomics and pharmaceuticals. According to the latest report added to ResearchAndMarkets.com’s offerings, the market is expected to grow from $1.3 billion in 2025 to $1.51 billion in 2026, marking a compound annual growth rate (CAGR) of 15.9%1.
Looking further ahead, the market is projected to reach $2.74 billion by 2030, with a CAGR of 16.1%. This growth is driven by several factors, including the integration of artificial intelligence in gene screening, the expansion of cloud-based genomics platforms, and the increasing use of personalized medicine. Automation in high-throughput screening workflows and the integration with multi-omics data are also significant trends shaping the market2.
The rising prevalence of genetic disorders is a key factor supporting the growth of the pooled CRISPR screening market. Factors such as advanced parental age, improved diagnostic capabilities, and wider access to genetic screening contribute to higher detection and reporting rates of these disorders. Pooled CRISPR screening allows researchers to perform genome-wide studies to identify genes associated with diseases, regulatory pathways, and potential therapeutic targets. For instance, the Cystic Fibrosis Trust noted an increase in registered cystic fibrosis patients in the UK from 11,148 in 2022 to 11,318 in 2023, a growth of about 1.5%3.
Technological innovations, such as transcriptome-wide profiling, are enhancing the market by enabling high-throughput functional genomics and more precise identification of therapeutic targets. Parse Biosciences Inc., for example, introduced CRISPR Detect in June 2023, a technology designed for large-scale, single-cell pooled CRISPR screening. This innovation, integrated with the Evercode Whole Transcriptome platform, matches individual gene perturbations with whole-transcriptome expression profiles across up to one million cells per experiment. This method addresses the limitations of droplet-based single-cell RNA sequencing and expands opportunities in genome-scale gene function analysis, regulatory network mapping, and drug discovery4.
Investment in research and development is accelerating the adoption of pooled CRISPR screening technologies. Increased funding enables biotechnology firms, pharmaceutical developers, and research institutions to enhance gene-editing tools, optimize experimental protocols, and improve screening accuracy. According to the UK Office for National Statistics, the UK government’s net spending on research and development rose by 8.2%, from £16.1 billion ($20.45 billion) in 2022 to £17.4 billion ($22.1 billion) in 2023. This trend of public and private investment is expected to continue, supporting the broader deployment of advanced CRISPR screening platforms5.
The market encompasses a range of products and services, including genome-wide and targeted screening solutions, libraries, reagents and kits, instruments, software, and services. Core technologies within the market include CRISPR-Cas9 screening, CRISPR interference screening, and CRISPR activation screening. Applications span functional genomics, drug discovery, cancer research, and gene regulation, with demand primarily from pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations.
Regionally, North America was the largest market for pooled CRISPR screening in 2025, driven by an established biotechnology infrastructure, substantial research funding, and the adoption of advanced genomics technologies. The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, with increasing investment in biotechnology, pharmaceutical research, and precision medicine. The market analysis includes regions such as Asia-Pacific, Southeast Asia, Western and Eastern Europe, North America, South America, the Middle East, and Africa, covering countries like Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.
Footnotes:
- The global pooled CRISPR screening market is projected to grow from $1.3 billion in 2025 to $1.51 billion in 2026. Source.
- Key growth factors include AI-enabled gene screening and cloud-based genomics platforms. Source.
- The number of cystic fibrosis patients in the UK increased by 1.5% from 2022 to 2023. Source.
- Parse Biosciences Inc. launched CRISPR Detect for high-scale, single-cell pooled CRISPR screening. Source.
- UK government net spending on research and development increased by 8.2% from 2022 to 2023. Source.
Featured Image: Megapixl @ Foxaon
